Skip to main content

methylene blue

Generic: METHYLENE BLUE·Brand: Hyophen, METHYLENE BLUE, PROVAYBLUE, Phosphasal, Prosed DS, Provayblue, Urelle, Uretron DS, Uribel, Uribel Tabs, Urimar Reformulated Oct 2013, Urin DS, Uro-Blue, Urogesic Blue Reformulated Apr 2012, Ustell, Utira

methylene blue: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

methylene blue evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect methylene blue to NEXS; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could methylene blue → NEXS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Septic Shock
Development Pipeline (2)
CompanyPhase
NEXUS BIOPHARMA INC (NEXS)Approved
NEXUS BIOPHARMA INC (NEXS)Approved
Clinical Trials (1)

Adjunctive Methylene BLUe in Septic SHock: a Pilot Randomized Controlled Trial

NCT06900140·Phase 3·ENTA
Recruiting

Primary endpoint: Enrolment/Recruitment Rate

InterventionalRandomizedsingle50 targetStarted 2025-06Completion 2026-052 sites · CanadaDr. Shannon M. Fernando
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Methylene blue injection is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Methylene blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.(NEXS)FDA ↗
ANDA217561UNKNOWNStandardIntravenousSolution

Frequently asked questions

Who is developing methylene blue?

methylene blue is being developed by NEXUS BIOPHARMA INC.

How many clinical trials involve methylene blue?

BioSniper tracks 1 clinical trial involving methylene blue.

What is methylene blue's latest FDA decision?

The most recent tracked FDA decision for methylene blue is Approval for 1 INDICATIONS AND USAGE Methylene blue injection is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. Methylene blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia., dated November 21, 2024.